The OGFOD1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphoblastoid cell line, designed to disrupt the gene encoding the prolyl 3,4-dihydroxylase OGFOD1. This product provides a heterogeneous pool of gene-edited cells, maintaining population-level diversity that is advantageous for studying gene function in the context of Burkitt lymphoma biology. The knockout is achieved through targeted gene disruption, resulting in a loss-of-function model without selection of individual clones.
The Raji cell line is an Epstein-Barr virus (EBV)-positive Burkitt lymphoma model established from a B-lymphoblastoid tumor. It is extensively characterized for its representation of B cell lymphomagenesis and oncogenic signaling pathways, particularly those driven by MYC overexpression. Raji cells grow in suspension and are highly tractable for a variety of cellular and molecular assays, making them a standard substrate for lymphoma research.
OGFOD1 catalyzes the prolyl 3,4-dihydroxylation of ribosomal protein RPS23, a post-translational modification that is essential for maintaining translational fidelity and ribosome integrity. This enzyme is regulated by ribosome biogenesis signals and is functionally linked to MYC in lymphoma contexts, where MYC-driven ribosomal activity influences OGFOD1 expression. Upon hydroxylation by OGFOD1, RPS23 participates in the 60S ribosomal subunit, directly impacting protein synthesis and cellular responses to stress. Loss of OGFOD1 disrupts this hydroxylation event, leading to altered translational output and potential stress-related phenotypes.
In the Raji background, OGFOD1 knockout provides a platform to investigate the intersection of ribosome biology and lymphomagenesis. The model is particularly relevant for exploring how translational control contributes to the proliferation and survival of Burkitt lymphoma cells, given MYC??s role in driving ribosome biogenesis and protein synthesis. By uncoupling hydroxylation from RPS23, researchers can assess the downstream effects on translational fidelity and identify vulnerabilities that may be exploited for therapeutic targeting in hematological malignancies and ribosomopathies.
This polyclonal knockout product is suitable for applications including translational control studies in B cell lymphoma, ribosome biology and protein hydroxylation research, and validation of ribosome-targeted inhibitors. Representative experimental techniques include Western blotting for OGFOD1 and RPS23 hydroxylation status, puromycin incorporation assays to monitor translation rates, polysome profiling to assess ribosome assembly, cell viability assessment by MTT assay, apoptosis detection via flow cytometry, and transcriptome analysis by RNA-seq. For further details or technical support, please contact Ascent Research.
